Nykode Therapeutics
Clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies.
Enterprise value
($51m)
Share price
NOK1.85 NYKD.OL
Company register number
990646066
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $45.0m | Private Placement VC |
| Total Funding | 000k | ||
EUREKA Network Projects(exited)
Kreftforeningen(exited)
Research Council of Norway(exited)
ShareLab(exited)
Anniken Fjelberg(exited)
Sarsia Seed Management(exited)
TD Veen(exited)
Innovation Norway(exited)
| NOK | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 387672 % | 31 % | (79 %) | 80 % | (33 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (19596 %) | 696 % | (31 %) | (684 %) | (324 %) | (496 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (19623 %) | 576 % | (28 %) | (596 %) | (272 %) | (447 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 41 % | 48 % | 374 % | 228 % | 457 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.